---
title: Impact of diet and lifestyle on cholesterol and heart health
videoId: Dyid7vWO0zI
---

From: [[foundmyfitness]] <br/> 

Cardiovascular disease remains the leading cause of death in the United States and globally for both men and women <a class="yt-timestamp" data-t="00:05:16">[00:05:16]</a>. A sobering statistic reveals that a little less than 50% of people's first symptom of coronary artery disease is sudden death <a class="yt-timestamp" data-t="00:00:00">[00:00:00]</a>, a fact emphasized in medical school <a class="yt-timestamp" data-t="00:00:08">[00:00:08]</a>. The understanding of [[the_relationship_between_cholesterol_and_heart_disease | atherosclerotic cardiovascular disease (ASCVD)]] is clearer than that of other chronic diseases like cancer or neurodegenerative diseases, offering more tools for prevention <a class="yt-timestamp" data-t="00:05:41">[00:05:41]</a>.

## Understanding Cholesterol and Lipoproteins

Cholesterol is an essential molecule, vital for cell fluidity and as a precursor to important hormones like testosterone, estrogen, progesterone, and cortisol <a class="yt-timestamp" data-t="00:08:34">[00:08:34]</a>. Every cell, except red blood cells, produces cholesterol, primarily the liver and steroidal tissues <a class="yt-timestamp" data-t="00:10:31">[00:10:31]</a>. To transport cholesterol, which is not water-soluble, through the blood (which is water), it must be encased in a water-soluble "ship" called a lipoprotein <a class="yt-timestamp" data-t="00:09:39">[00:09:39]</a>.

The most critical measurement for [[role_of_ldl_and_statins_in_managing_heart_disease_risk | cardiovascular disease risk]] is the concentration of ApoB (Apolipoprotein B) particles <a class="yt-timestamp" data-t="00:12:32">[00:12:32]</a>. ApoB is the structural apoprotein found on low-density lipoproteins (LDLs), intermediate-density lipoproteins (IDLs), and very low-density lipoproteins (VLDLs) <a class="yt-timestamp" data-t="00:10:07">[00:10:07]</a>.

### Why ApoB is Preferred Over LDL-C

While total cholesterol was initially measured in the 1950s <a class="yt-timestamp" data-t="00:11:13">[00:11:13]</a>, and later LDL cholesterol (LDL-C) became a stronger predictor <a class="yt-timestamp" data-t="00:12:11">[00:12:11]</a>, ApoB is now considered a superior predictor of ASCVD risk <a class="yt-timestamp" data-t="00:14:57">[00:14:57]</a>.

*   **Accuracy of Measurement**: LDL-C is often estimated using the Friedewald equation, which can be inaccurate <a class="yt-timestamp" data-t="00:14:17">[00:14:17]</a>. Direct measurement of LDL-C is better, but still inferior to ApoB <a class="yt-timestamp" data-t="00:14:49">[00:14:49]</a>.
*   **Total Atherogenic Burden**: ApoB encompasses the total atherogenic burden by measuring the concentration of all particles capable of initiating and progressing atherosclerosis <a class="yt-timestamp" data-t="00:17:50">[00:17:50]</a>.
*   **Missing VLDL Risk**: Relying solely on LDL particle number (LDL-P) or LDL-C can miss high atherogenic risk in individuals with elevated VLDL <a class="yt-timestamp" data-t="00:18:04">[00:18:04]</a>. ApoB accounts for this <a class="yt-timestamp" data-t="00:18:24">[00:18:24]</a>.
*   **Clearance Issues**: An elevated ApoB level often indicates issues with the clearance of these particles, primarily related to the function and number of LDL receptors on the liver <a class="yt-timestamp" data-t="00:19:44">[00:19:44]</a>.

ApoB levels rise with age, primarily due to issues with clearance rather than synthesis <a class="yt-timestamp" data-t="00:27:19">[00:27:19]</a>.
Physiologically, children are born with very low ApoB levels, typically below 20 mg/dL, indicating that high levels are not necessary for growth and development <a class="yt-timestamp" data-t="00:32:32">[00:32:32]</a>. An ApoB level below 20-30 mg/dL is believed to prevent the development of atherosclerosis <a class="yt-timestamp" data-t="00:33:57">[00:33:57]</a>. Achieving a lifetime ceiling of 60 mg/dL would also result in a very low-risk individual <a class="yt-timestamp" data-t="00:35:31">[00:35:31]</a>.

> "Apolipoprotein B is not just associated with cardiovascular disease, but it's causally linked to it, meaning it causes ASCVD" <a class="yt-timestamp" data-t="00:24:20">[00:24:20]</a>.

The approach to managing ApoB should be similar to how smoking is managed for lung cancer: eliminate the causal factor as soon as possible <a class="yt-timestamp" data-t="00:25:42">[00:25:42]</a>. Atherosclerosis is an "area under the curve" problem, accumulating over decades, so early intervention is key <a class="yt-timestamp" data-t="00:26:05">[00:26:05]</a>.

## [[Impact of diet and nutrition on cholesterol levels | Dietary Practices]] and Lipid Health

For generally healthy individuals aiming to lower ApoB through diet and lifestyle, two major dietary factors play a role:

1.  **Insulin Resistance**: This primarily impacts ApoB through the VLDL-triglyceride pathway <a class="yt-timestamp" data-t="00:37:51">[00:37:51]</a>. Higher triglyceride burdens lead to higher ApoB burdens because more "ships" are needed to carry the "cargo" of cholesterol and triglycerides <a class="yt-timestamp" data-t="00:38:42">[00:38:42]</a>.
    *   **Carbohydrate Restriction**: This is considered the most effective dietary tool for triglyceride reduction, specifically focusing on refined and starchy carbohydrates <a class="yt-timestamp" data-t="00:39:53">[00:39:53]</a>.
2.  **Saturated Fat Consumption**: Saturated fat impacts ApoB in two ways:
    *   Directly influencing cholesterol synthesis <a class="yt-timestamp" data-t="00:40:16">[00:40:16]</a>.
    *   Inhibiting the sterile regulatory binding protein in the liver, leading to fewer LDL receptors being made <a class="yt-timestamp" data-t="00:41:10">[00:41:10]</a>.

The individual response to saturated fat varies due to genetic differences <a class="yt-timestamp" data-t="00:42:12">[00:42:12]</a>. If saturated fat intake causes ApoB levels to rise, swapping it with monounsaturated fat (e.g., olive oil) can often fix the problem <a class="yt-timestamp" data-t="00:43:05">[00:43:05]</a>.

> "Use nutrition to solve the nutrition problem... and let your lipids fall where they may because this is one of the few areas in medicine where we have amazing pharmacologic tools" <a class="yt-timestamp" data-t="00:45:14">[00:45:14]</a>.

## [[role_of_ldl_and_statins_in_managing_heart_disease_risk | Pharmacological Interventions]] for Lipid Management

The landscape of lipid-lowering drugs has evolved significantly:

*   **Statins**: Introduced in 1987, statins inhibit the first committed step of cholesterol synthesis, primarily in the liver <a class="yt-timestamp" data-t="00:56:58">[00:56:58]</a>. This causes the liver to increase LDL receptor production, pulling more LDL from circulation <a class="yt-timestamp" data-t="00:57:48">[00:57:48]</a>.
    *   **Side Effects**: About 7% of people develop reversible muscle aches <a class="yt-timestamp" data-t="00:58:04">[00:58:04]</a>. A small subset (around 4%) might develop type 2 diabetes due to increased insulin resistance <a class="yt-timestamp" data-t="00:58:26">[00:58:26]</a>. Liver function tests (transaminases) can also increase <a class="yt-timestamp" data-t="00:59:40">[00:59:40]</a>.
    *   **Mitochondrial Function**: Statins can affect the HMG-CoA reductase pathway, which is also important for CoQ10 synthesis, vital for mitochondrial function <a class="yt-timestamp" data-t="01:00:43">[01:00:43]</a>. However, direct functional impact on mitochondrial function (e.g., via Zone 2 exercise testing) appears to be very small, if any <a class="yt-timestamp" data-t="01:01:57">[01:01:57]</a>. CoQ10 supplementation has not consistently shown to reduce muscle soreness in clinical trials <a class="yt-timestamp" data-t="01:07:00">[01:07:00]</a>.
    *   **Neurodegenerative Disease**: Studies looking at statin use and the incidence of Alzheimer's disease or dementia as a secondary outcome have consistently found neutral to beneficial effects <a class="yt-timestamp" data-t="01:16:06">[01:16:06]</a>. There was no difference between hydrophobic and hydrophilic statins in these outcomes <a class="yt-timestamp" data-t="01:16:53">[01:16:53]</a>. However, very low desmosterol levels (a proxy for brain cholesterol synthesis) might increase the risk of AD and dementia <a class="yt-timestamp" data-t="01:19:54">[01:19:54]</a>.
*   **Ezetimibe (Zetia)**: This drug works by impairing cholesterol reabsorption in the gut, which also leads the liver to increase LDL receptors <a class="yt-timestamp" data-t="01:24:30">[01:24:30]</a>. It is less potent than statins and particularly effective in patients with defective ATP binding cassettes in their gut, which leads to high phytosterol levels <a class="yt-timestamp" data-t="01:25:07">[01:25:07]</a>.
*   **PCSK9 Inhibitors**: Discovered based on observations of individuals with naturally very low LDL-C due to a hypofunctioning PCSK9 gene <a class="yt-timestamp" data-t="01:22:15">[01:22:15]</a>, these drugs directly inhibit PCSK9, a protein that degrades LDL receptors <a class="yt-timestamp" data-t="02:11:13">[02:11:13]</a>. They are highly effective at lowering ApoB and have zero side effects <a class="yt-timestamp" data-t="02:11:13">[02:11:13]</a>, but are expensive and often require specific criteria for insurance coverage <a class="yt-timestamp" data-t="02:22:56">[02:22:56]</a>.
*   **Bempedoic Acid**: This prodrug inhibits cholesterol synthesis only in the liver, avoiding systemic side effects seen with statins <a class="yt-timestamp" data-t="02:28:01">[02:28:01]</a>. It also leads to increased LDL receptors and lowers ApoB <a class="yt-timestamp" data-t="02:28:34">[02:28:34]</a>. Like PCSK9 inhibitors, it is expensive <a class="yt-timestamp" data-t="02:28:52">[02:28:52]</a>.
*   **Berberine**: A systematic review suggested berberine can lower LDL cholesterol and potentially reduce statin myopathy, and may lower the effective dose of statins needed <a class="yt-timestamp" data-t="01:34:15">[01:34:15]</a>. It is a mitochondrial toxin, similar to metformin, as a complex 1 inhibitor <a class="yt-timestamp" data-t="01:34:55">[01:34:55]</a>.

## [[impact_of_lifestyle_habits_on_aging_and_longevity | Lifestyle Factors]] Influencing Heart Health

Beyond diet and pharmacological interventions, several lifestyle factors significantly impact heart health:

### Exercise and Metabolic Health

Exercise is crucial for improving [[lifestyle_factors_influencing_intestinal_health | insulin sensitivity]] and [[impact_of_lifestyle_choices_on_glucose_regulation | glucose regulation]] <a class="yt-timestamp" data-t="01:46:13">[01:46:13]</a>.

*   **Glucose Disposal**: Muscles are the primary "sink" for glucose disposal <a class="yt-timestamp" data-t="01:41:12">[01:41:12]</a>. Both insulin-dependent and insulin-independent mechanisms (muscle contraction during exercise) facilitate glucose transport into muscle cells <a class="yt-timestamp" data-t="01:42:11">[01:42:11]</a>.
*   **Chronic Glucose Toxicity**: Chronically elevated glucose levels are damaging to small vessels (microvasculature of eyes, kidneys, heart, brain) <a class="yt-timestamp" data-t="01:43:48">[01:43:48]</a>, while elevated insulin levels damage large blood vessels <a class="yt-timestamp" data-t="01:44:59">[01:44:59]</a>. This can shorten life expectancy by as much as 10 years <a class="yt-timestamp" data-t="01:43:32">[01:43:32]</a>.
*   **Metabolic Flexibility**: The ability to efficiently switch between using glucose and fatty acids as fuel substrates is a hallmark of health <a class="yt-timestamp" data-t="01:52:31">[01:52:31]</a>.
    *   **Zone 2 Training**: Engaging in Zone 2 exercise (sustaining effort where conversation is possible but uncomfortable) for 80% of cardio training time is crucial for expanding mitochondrial capacity and enhancing metabolic flexibility <a class="yt-timestamp" data-t="01:52:50">[01:52:50]</a>.
    *   **VO2 Max**: This measure of cardiorespiratory fitness is strongly correlated with health and longevity <a class="yt-timestamp" data-t="02:06:35">[02:06:35]</a>. The difference in risk between the bottom 25th percentile and top 2.5th percentile of VO2 Max is a five-fold higher all-cause mortality risk for the lower group <a class="yt-timestamp" data-t="02:07:11">[02:07:11]</a>.

### Sleep

Sleep disruptions, both acute and chronic, significantly impair [[impact_of_lifestyle_choices_on_glucose_regulation | glucose regulation]] and insulin sensitivity <a class="yt-timestamp" data-t="01:46:26">[01:46:26]</a>. Even a few days of reduced sleep (4-6 hours/night) can lead to a 50% reduction in glucose disposal ability <a class="yt-timestamp" data-t="01:47:18">[01:47:18]</a>.

### Stress

Chronic stress and hypercortisolemia can contribute to [[lifestyle_factors_influencing_intestinal_health | insulin resistance]] <a class="yt-timestamp" data-t="02:11:53">[02:11:53]</a>. Managing stress through practices like exercise, sufficient sleep, and therapy can widen the "buffer zone" for distress tolerance <a class="yt-timestamp" data-t="03:50:03">[03:50:03]</a>.

### Hormonal Balance

*   **Estrogen (Women)**: The sharp decline in estrogen, progesterone, and testosterone during menopause significantly impacts bone density, cardiovascular health, and potentially Alzheimer's risk <a class="yt-timestamp" data-t="02:38:15">[02:38:15]</a>.
    *   Hormone Replacement Therapy (HRT) at the time of menopause initiation is shown to reduce the risk of heart disease, dementia (especially in ApoE4 women), and preserve bone mineral density (BMD) <a class="yt-timestamp" data-t="03:01:02">[03:01:02]</a>.
    *   The Women's Health Initiative (WHI) study, widely misinterpreted, did not show that estrogen increased breast cancer risk or mortality <a class="yt-timestamp" data-t="02:42:28">[02:42:28]</a>. Issues stemmed from the use of a synthetic progestin (MPA) and older participant age <a class="yt-timestamp" data-t="02:47:28">[02:47:28]</a>.
    *   Transdermal (patch) estrogen is preferred over oral forms due to lower risks of hypercoagulability <a class="yt-timestamp" data-t="02:52:50">[02:52:50]</a>.
*   **Testosterone (Men and Women)**: Male testosterone levels gradually decline from the 20s <a class="yt-timestamp" data-t="03:20:41">[03:20:41]</a>. For both men and women, testosterone replacement therapy can improve muscle mass, energy, and mood <a class="yt-timestamp" data-t="03:14:57">[03:14:57]</a>.
    *   For men, lower testosterone is associated with a higher risk of high-grade prostate cancer <a class="yt-timestamp" data-t="03:27:08">[03:27:08]</a>. Testosterone replacement does not increase prostate cancer risk, but can increase prostate size (BPH) <a class="yt-timestamp" data-t="03:27:16">[03:27:16]</a>.
    *   There might be a slight, short-term increase in cardiovascular event risk in susceptible men on testosterone replacement, potentially due to increased blood pressure <a class="yt-timestamp" data-t="03:28:46">[03:28:46]</a>. Therefore, it's advised to manage other risk factors like blood pressure before initiating treatment <a class="yt-timestamp" data-t="03:29:32">[03:29:32]</a>.
    *   Injections (twice weekly) are preferred for more consistent levels over gels <a class="yt-timestamp" data-t="03:26:19">[03:26:19]</a>.

## Diagnostic and Monitoring Tools for Heart Health

*   **CT Angiogram (CTA)**: Can provide a clear picture of plaque accumulation in arteries <a class="yt-timestamp" data-t="03:29:23">[03:29:23]</a>. It is most helpful when it reveals a positive finding in a young person or a negative finding in an old person, influencing treatment aggressiveness <a class="yt-timestamp" data-t="03:31:58">[03:31:58]</a>. The radiation dose has significantly decreased over the years (<1 mSv today compared to 20 mSv two decades ago) <a class="yt-timestamp" data-t="03:34:51">[03:34:51]</a>.
*   **Blood Pressure Monitoring**: Target blood pressure should be 120/80 mmHg or lower, based on the SPRINT trial <a class="yt-timestamp" data-t="03:29:43">[03:29:43]</a>. Automated cuffs at home are recommended for accurate measurement. The protocol involves sitting for 5 minutes without stimulation, then taking two more readings, with the average of these readings used <a class="yt-timestamp" data-t="03:36:31">[03:36:31]</a>. Proper arm position (cuff 2 inches above elbow, at right atrium level) is crucial <a class="yt-timestamp" data-t="03:37:06">[03:37:06]</a>.
*   **Continuous Glucose Monitors (CGMs)**: Can track average blood glucose, postprandial spikes, and variability, offering insight into [[impact_of_lifestyle_choices_on_glucose_regulation | glucose regulation]] <a class="yt-timestamp" data-t="01:50:59">[01:50:59]</a>. Lower average blood glucose is associated with better all-cause mortality outcomes, even within "normal" ranges (e.g., 5% HbA1c is better than 5.5%) <a class="yt-timestamp" data-t="01:49:00">[01:49:00]</a>.
*   **Cholesterol Synthesis Markers (Desmosterol, Lathosterol)**: These can be measured (e.g., at Boston Heart Lab) to assess brain and peripheral cholesterol synthesis respectively <a class="yt-timestamp" data-t="01:19:32">[01:19:32]</a>. Low desmosterol levels have been linked to increased risk of Alzheimer's and dementia <a class="yt-timestamp" data-t="01:19:54">[01:19:54]</a>.
*   **Phytosterols (Cytostanol, Campesterol)**: High levels can indicate a defective ATP binding cassette in the gut, which means the body is absorbing too many phytosterols that are potentially more atherogenic than cholesterol <a class="yt-timestamp" data-t="02:25:07">[02:25:07]</a>.

## Beyond Standard Care

Aggressive prevention in medicine (often termed "Medicine 3.0") aims for highly preventive, personalized care <a class="yt-timestamp" data-t="03:42:14">[03:42:14]</a>. This often involves tests and frequencies of screening beyond standard care, incurring costs and potential emotional burden from false positives <a class="yt-timestamp" data-t="03:19:18">[03:19:18]</a>. Understanding test sensitivity, specificity, and predictive values is essential for managing expectations <a class="yt-timestamp" data-t="03:19:32">[03:19:32]</a>.